SARS‐CoV‐2 serology in patients on biological therapy or apremilast for psoriasis: a study of 93 patients in the Italian red zone
| Autor: | Catherine Klersy, Valeria Musella, Paola Zelini, Daniele Lilleri, Carlo Tomasini, Martina Volontè, Camilla Vassallo, Eugenio Isoletta, Valeria Brazzelli, Syed M A Ahmed |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Dermatology Severity of Illness Index Letters To The Editor Serology Psoriasis Pandemic Humans Medicine In patient Letter to the Editor SARS-CoV-2 business.industry Anti-Inflammatory Agents Non-Steroidal COVID-19 medicine.disease Thalidomide Biological Therapy Infectious Diseases Apremilast business medicine.drug |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology |
| ISSN: | 1468-3083 0926-9959 |
| DOI: | 10.1111/jdv.17721 |
| Popis: | Lombardy, Italy was one of the most heavily impacted areas in the world during the height of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, quickly becoming the epicenter within Italy. There have been 845,898 cases reported to date July 19, 2021 within Lombardy, accounting for approximately 20% of the cases overall in Italy.1 During the height of the pandemic, concern was raised over the use of biologics for psoriasis as they necessitate some degree of immunomodulation.2. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text